Orbus Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 9
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $10M
Latest Deal Amount
  • Investors
  • 6

Orbus Therapeutics General Information

Description

Developer of medicinal products designed to improve the health and quality of life for patients with rare diseases. The company's medical product is an irreversible inhibitor of ornithine decarboxylase (ODC) that delays or freezes tumor growth by inhibiting the production of the enzyme, enabling medical professionals to prevent tumor growth in certain types of cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • 2479 East Bayshore Road
  • Suite 105
  • Palo Alto, CA 94303
  • United States
+1 (650) 000-0000

Orbus Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orbus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 11-Aug-2020 $10M 0000 00000 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series A3) 000 0000 0000 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A2) 20-Mar-2019 $18.5M $51M 000.00 Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 19-Aug-2015 $32.5M $32.5M 000.00 Completed Clinical Trials - Phase 3
To view Orbus Therapeutics’s complete valuation and funding history, request access »

Orbus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-4 00,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-3 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 26,452,884 $0.010000 $1.01 $1.01 1x $1.01 31.5%
Series A 21,428,577 $0.010000 $0.84 $0.84 1x $0.84 25.52%
To view Orbus Therapeutics’s complete cap table history, request access »

Orbus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of medicinal products designed to improve the health and quality of life for patients with rare diseases. The
Drug Discovery
Palo Alto, CA
9 As of 2017
0000
0000 0000-00-00
00000000000 0000

0000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000 000000000
San Diego, CA
0 As of 0000
00000
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Orbus Therapeutics Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
0000000 Corporate Backed or Acquired San Diego, CA 0 00000 000000&0 00000
You’re viewing 1 of 1 competitors. Get the full list »

Orbus Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Robert Myers Co-Founder, President, Chief Executive Officer & Board Member
Victor Levin Co-Founder and Medical Advisor
Jason Levin Co-Founder, Board Member & Chief Operating Officer
To view Orbus Therapeutics’s complete executive team members history, request access »

Orbus Therapeutics Board Members (8)

Name Representing Role Since
Ernest Mario Ph.D Self Chairman 000 0000
Geeta Vemuri Ph.D Agent Capital Board Observer 000 0000
Jason Levin Orbus Therapeutics Co-Founder, Board Member & Chief Operating Officer 000 0000
Kurt Emster Orbus Therapeutics Board Member 000 0000
Michael Wasserman Ph.D H.I.G. BioHealth Partners Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Orbus Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orbus Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Management Venture Capital Minority 000 0000 000000 0
Agent Capital Venture Capital Minority 000 0000 000000 0
Adams Street Partners Fund of Funds Minority 000 0000 000000 0
Ernest Mario Angel (individual) Minority 000 0000 000000 0
H.I.G. BioHealth Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »